Strong study results and virtual presentation of ASTar
Second quarter, 1 April -
· Net sales amounted to
· The operating result totalled
· The result for the period amounted to
· Earnings per share before and after dilution amounted to
· Cash flow from operating activities totalled
Period, 1 January-
· Net sales amounted to
· The operating result totalled
· The result for the period amounted to
· Earnings per share before and after dilution amounted to
· Cash flow from operating activities totalled
· At
Significant events
in the second quarter of 2020
· Q-linea carried out a directed issue of four million shares in
· Q-linea announced positive results from prospective study with ASTar.
· The Annual General Meeting was held on 26 May. Refer to "Other information" for information about the resolutions passed at the Annual General Meeting.
after the end of the period
· No significant events took place after the end of the period.
Comments by the CEO
Strong study results and virtual presentation of ASTar
After an intense quarter - during a year marked by the coronavirus pandemic - I am pleased to present Q-linea's progress in its efforts to bring its key product, ASTar, to market.
The pandemic has naturally affected the mood at Q-linea, but we have thankfully been spared most of its direct and indirect effects. While the situation could certainly change as more countries relax their travel and social distancing restrictions, we remain cautiously positive.
Despite the challenges of the pandemic, such as the need to conduct digital meetings rather than in-person meetings, our collaboration with
During the quarter, we held our first market presentation of ASTar, during which we shared a little more information about the underlying technology. Our aim is to show how well-thought-out ASTar is in order to convincingly demonstrate the major benefits it will offer. The presentation is still available on our website, and the overall response has been highly positive.
In May, we announced excellent results from a prospective patient study conducted together with the laboratory for clinical microbiology at
In the study, ASTar analysed samples from 17 patients and the antibiotic panel consisted of 29 antibiotic preparations, covering both fastidious1 and non-fastidious bacteria. The results (Essential Agreement: 94.5%, Categorical Agreement: 97.3%) were well above the regulatory requirements for the EU and the US (at least 90% in both categories).
These strong results and our positive collaboration bode well for the major prospective performance study involving 80 to 100 patients to be carried out in the autumn. In addition, we can also announce that we have signed a contract with
The prospective clinical part of the study is expected to take approximately three months and will initially start in
At the Annual General Meeting in May,
In summary, I am proud of what we achieved during the quarter and know that we still have an interesting and intense journey ahead of us. During the quarter, we carried out a directed issue that raised gross proceeds of
Uppsala,
Jonas Jarvius, President
[1] Bacteria that require richer growth media to perform AST analyses
This report has been prepared in a Swedish original and an English translation. In the event of any discrepancies between the two, the Swedish version is to apply.
Presentation
Q-linea invites investors, analysts and the media to an audiocast and teleconference (in English) today, 16 July, at
Telephone number for the teleconference: SE: +46851999383
Upcoming reporting dates
[]
Week of April 12[th] Annual Report 2020
About the company
Corporate Reg. Number: 556729-0217
Registered office: Uppsala
Contact: Dag Hammarskjölds väg 52 A, www.qlinea.com
SE-752 37, Uppsala, Sweden E-post: contact@qlinea.com
Tel: +46 18-444 3610
For questions about the report, contact:
Jonas Tel: +46 70 323 7760 E-post: jonas.jarvius@qlinea.com
Jarvius,
President
Anders Tel: +46 70 600 1520 E-post: anders.lundin@qlinea.com
Lundin, CFO &
IR
This information is information that
About Q-linea
Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Q-linea's vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.
https://news.cision.com/q-linea/r/interim-report-1-january---30-june-2020,c3154959
https://mb.cision.com/Main/17731/3154959/1279787.pdf
https://mb.cision.com/Public/17731/3154959/87d8913e1ad5ec8a.pdf
(c) 2020 Cision. All rights reserved., source